VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 10, 2008) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that it had commenced dosing in a Phase I clinical trial to evaluate the pharmacokinetics of AL-108 (intranasal administration) or AL-208 (intravenous administration) in the blood and cerebrospinal fluid (CSF) of healthy adult subjects.
